Neurotech International (ASX:NTI) signed an agreement with RH Farma Dooel Skopje, a subsidiary of European Cannabis Company, to develop cannabinoid therapies, according to a Thursday filing with the Australian bourse.
The development aims to create a pharmaceutical-grade broad-spectrum cannabinoid drug product for pediatric neurodevelopmental disorders, the filing said.
The agreement involves an initial payment of 25,000 euros, with additional services to be provided over a 12-month term, according to the filing.
Neurotech International's shares fell past 2% in recent Friday trade.
Price (AUD): $0.04, Change: $-0.0010, Percent Change: -2.27%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.